research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
For marine organisms, the details of the photosynthesis reactions are less well understood, and the δ13C values for marine photosynthetic organisms are dependent on temperature. At higher temperatures, CO2 has poor solubility in water, which means there is less CO2 available for the photosynthetic reactions. Under these conditions, fractionation is reduced, and at temperatures above 14 °C the δ13C values are correspondingly higher, while at lower temperatures, CO2 becomes more soluble and hence more available to marine organisms. The δ13C value for animals depends on their diet. An animal that eats food with high δ13C values will have a higher δ13C than one that eats food with lower δ13C values. The animal's own biochemical processes can also impact the results: for example, both bone minerals and bone collagen typically have a higher concentration of 13C than is found in the animal's diet, though for different biochemical reasons. The enrichment of bone 13C also implies that excreted material is depleted in 13C relative to the diet. Since 13C makes up about 1% of the carbon in a sample, the 13C/12C ratio can be accurately measured by mass spectrometry. Typical values of δ13C have been found by experiment for many plants, as well as for different parts of animals such as bone collagen, but when dating a given sample it is better to determine the δ13C value for that sample directly than to rely on the published values.
The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue. In February 2012, Bristol-Myers/Astra Zeneca distributed additional safety information on saxagliptin use in South Africa. The package insert is to be edited for South Africa. Contraindications will now include a history of sensitivity to saxagliptin (or another DPP4 inhibitor) as well as pancreatitis. Spontaneously reported adverse events in South Africa have included anaphylaxis, angioedema and acute pancreatitis. In a cardiovascular outcomes trial, saxagliptin treatment let to a small increase in the risk of being hospitalized for heart failure. Saxagliptin may cause joint pain that can be severe and disabling. Saxagliptin may increase the risk of heart failure.
The commission noted that such incidents in July and August 2008 "could no longer be countered by the JPKF" and "reactivating the peacekeeping mechanism was not an alternative means of redress available for Georgia." It also noted that Georgian attack on Tskhinvali on 7 August was a response, albeit not proportionate, to South Ossetian attacks in the following paragraphs:
Sources: en.wikipedia.org
TikTok is fined £12.7m by the Information Commissioner's Office for failing to protect the privacy of children after sharing their information without parental permission. Immigration Minister Robert Jenrick is given a six-month driving ban by magistrates after he was caught speeding on the M1. Former prime minister of New Zealand Jacinda Ardern is appointed a trustee of the Prince of Wales' Earthshot Prize. British boxer Amir Kahn is banned from competing professionally for two years after an anti-doping test revealed the presence of a banned substance following his February 2022 fight with Kell Brook. Coronation of Charles III and Camilla The official invitation from King Charles III and Queen Camilla is unveiled and sent to about 2,000 guests. Madame Tussauds Blackpool announce that a new waxwork of King Charles III will be unveiled in May. 5 April The government confirms plans to use the vessel Bibby Stockholm to house around 500 male migrants off the Dorset Coast, citing the cheaper cost of doing so compared to housing them in hotels. A BBC News investigation claims the life coaching organisation Lighthouse is operated as a cult. The White House press secretary, Karine Jean-Pierre, said that US president Joe Biden has accepted an invitation from King Charles for an undated state visit to the United Kingdom. 6 April Buckingham Palace announces that it is co-operating with a study being jointly conducted by the University of Manchester and Historic Royal Palaces that is exploring links between the British monarchy and the slave trade in the 17th and 18th centuries.
== Research == Much of the research conducted on demyelinating diseases is targeted towards discovering the mechanisms by which these disorders function in an attempt to develop therapies and treatments for individuals affected by these conditions. For example, proteomics has revealed several proteins which contribute to the pathophysiology of demyelinating diseases. For example, COX-2 has been implicated in oligodendrocyte death in animal models of demyelination. The presence of myelin debris has been correlated with damaging inflammation as well as poor regeneration, due to the presence of inhibitory myelin components. N-cadherin is expressed in regions of active remyelination and may play an important role in generating a local environment conducive to remyelination. N-cadherin agonists have been identified and observed to stimulate neurite growth and cell migration, key aspects of promoting axon growth and remyelination after injury or disease. Immunomodulatory drugs such as fingolimod have been shown to reduce immune-mediated damage to the CNS, preventing further damage in patients with MS. The drug targets the role of macrophages in disease progression. CNS-selective thyromimetics may become a viable strategy to protect myelin and promote remyelination in MS patients. It has been shown that intranasal administration of apotransferrin (aTf) can protect myelin and induce remyelination in mice. Finally, electrical stimulation which activates neural stem cells may provide a method by which regions of demyelination can be repaired.
Unable to afford the TCB Band, the group featured guitarists Jock Bartley and Larry Coryell, Neil Flanz on pedal steel, bassist Kyle Tullis, and drummer N. D. Smart. The touring party also included Parsons' new wife, Gretchen Parsons, who was envious of Harris and her young daughter. Coordinating the spectacle as road manager was Phil Kaufman, who had served time with Charles Manson on Terminal Island but who ensured that the performer stayed clear of drugs and limited his alcohol intake during shows. At first, the band was under-rehearsed and played poorly; however, they improved with steady gigging and received rapturous responses at several counter-cultural venues, including Armadillo World Headquarters in Austin, Max's Kansas City in New York City, and Liberty Hall in Houston, where Neil Young and Linda Ronstadt sat in for a filmed performance. Nevertheless, the tour failed to galvanize sales of GP, which never charted in the Billboard 200. For his next and final album, 1974's posthumously released Grievous Angel, Parsons used Harris and members of the TCB Band. The record received more enthusiastic reviews than GP. Although Parsons only contributed two new songs to the album ("In My Hour of Darkness" and "Return of the Grievous Angel"), he was reportedly enthusiastic with his new sound and seemed to have finally adopted a diligent mindset to his musical career, limiting his intake of alcohol and opiates during most of the sessions. Grievous Angel peaked at number 195 on the Billboard chart.
=== In vitro studies === Cell culture studies have reported that D-ribose-L-cysteine increases glutathione levels and modulates oxidative stress responses in normal cell lines exposed to cytotoxic agents.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.